Steve Grasso, Grasso Global CEO, joins 'Power Lunch' to discuss stock plays for three stocks.

The document notes that a phase 1 trial of two experimental Moderna RSV vaccines in infants aged five to eight months was ...

Moderna has struggled in the post-COVID era, making its capacity to generate free cash flows doubtful. See why MRNA stock is ...

The vaccine maker previously revealed plans to slash R&D budget to conserve cash for product launches, but after a rough year ...

Nasdaq Inc's (NASDAQ:NDAQ) annual reconstitution of the Nasdaq-100 Index will become effective before the market opens on ...

Moderna Inc. closed $129.71 short of its 52-week high ($170.47), which the company achieved on May 24th.

Short interest for healthcare stocks in S&P 500 rose in November vs. October, while Moderna continued to be the most shorted ...

Most years, I find one or two stocks among the biggest losers that I think are worth buying. This year there are three — ...

Shares of Moderna Inc. MRNA inched 0.02% higher to $41.84 Monday, on what proved to be an all-around mixed trading session ...

Two days after the FDA revealed that it had halted enrollment in trials of respiratory syncytial virus (RSV) vaccines that ...

Moderna contended in documents that it needs the larger, higher sign because it's blocked from anywhere other than right in front of the building by trees in the public park betwe ...

Moderna faces index removal, stock plunge, vaccine challenges, and lawsuits, while focusing on R&D in oncology and rare diseases for future growth.